BAG2

BAG2 Full Name

BCL2-associated athanogene 2

BAG2 Introduction

BAG2 (BCL2-associated athanogene 2) is a member of the BAG family of co-chaperone proteins that regulate protein homeostasis, stress responses, and cell survival by interacting with molecular chaperones such as Hsp70/Hsc70. As a key regulator of the ubiquitin–proteasome system, BAG2 contains a conserved BAG domain that mediates protein–protein interactions and modulates the activity of chaperone complexes involved in protein folding and degradation. For researchers investigating mechanisms of tumor progression, neurodegeneration, and cellular stress adaptation, BAG2 has attracted increasing attention because abnormal regulation of protein quality control pathways is closely associated with disease development. Emerging evidence indicates that BAG2 functions as a molecular switch controlling the balance between protein stabilization and degradation, thereby influencing cellular fate under physiological and pathological conditions.

BAG2 plays important roles in maintaining cellular homeostasis through multiple signaling pathways. It has been reported to regulate the stability of specific client proteins by modulating Hsp70-associated complexes and inhibiting certain ubiquitin ligase activities. In cancer biology, BAG2 can affect tumor cell proliferation, apoptosis resistance, invasion, and stress tolerance by altering the stability of oncogenic or tumor suppressive proteins. Recent studies have also identified BAG2 as a regulator of innate immune signaling. BAG2 can interact with STUB1 (also known as CHIP) to prevent excessive K48-linked ubiquitination of STING, leading to STING stabilization and enhanced type I interferon signaling. In addition, BAG2 has been implicated in mitochondrial quality control and mitophagy regulation, where it may influence PINK1/PARKIN-mediated mitochondrial clearance, highlighting its potential role in protecting cells from oxidative stress and mitochondrial dysfunction.

Dysregulation of BAG2 expression has been linked to several human diseases, particularly cancer and disorders associated with impaired protein homeostasis. In hepatocellular carcinoma, elevated BAG2 expression has been associated with tumor progression, increased proliferative capacity, enhanced invasion, and unfavorable clinical outcomes, suggesting its potential value as a prognostic biomarker and therapeutic target. Conversely, in cervical cancer, BAG2 has been reported to exert a tumor-suppressive function by stabilizing STING and promoting antitumor immune responses, indicating that BAG2 activity may be highly context-dependent depending on cellular environment and signaling networks. Beyond oncology, BAG2-related regulation of chaperone systems, mitochondrial function, and stress responses suggests broader implications in neurodegenerative diseases and aging-related disorders. Understanding BAG2-mediated molecular mechanisms may provide new opportunities for developing targeted therapies aimed at restoring protein homeostasis and improving disease treatment strategies.

Alternate Names for BAG2

BAG2; BCL2-associated athanogene 2; BAG family molecular chaperone regulator 2; bcl-2-associated athanogene 2; BAG-family molecular chaperone regulator-2; dJ417I1.2 (BAG-family molecular chaperone regulator 2); BAG-2; dJ417I1.2; KIAA0576; MGC149462;

• 1.Zhu Q, Yu S. The role of cGAS-STING signaling in HPV infection and HPV-related cancers. Front Immunol. 2025, 16:1709613.
  2.Pattingre S, Turtoi A. BAG Family Members as Mitophagy Regulators in Mammals. Cells. 2022, 11(4):681.